Navigation Links
Soligenix Reports First Quarter 2010 Financial Results and Reviews Accomplishments
Date:5/17/2010

successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec® for gastrointestinal GVHD include the risks that: the FDA's requirement that Soligenix conduct additional clinical trials to demonstrate the safety and efficacy of orBec® will take a significant amount of time and money to complete and positive results leading to regulatory approval cannot be assumed; Soligenix is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; orBec® may not gain market acceptance if it is eventually approved by the FDA; and others may develop technologies or products superior to orBec®. Factors affecting the development and use of SGX201 and LPM™ are similar to those affecting orBec®. These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.


'/>"/>
SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Soligenix Announces Completion of Patient Enrollment in Phase 2 Acute GVHD Prevention Clinical Trial
2. Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
3. Soligenix to Present at 12th Annual BIO CEO & Investor Conference
4. Soligenix Reports Third Quarter 2009 Financial Results
5. Soligenix to Present at 8th Annual BIO Investor Forum
6. Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors
7. DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol SNGX
8. Sinovac Reports Unaudited First Quarter 2010 Financial Results
9. Microbix Reports a Record Increase in Worldwide Sales for 2nd Quarter 2010
10. Transdel Pharmaceuticals Reports First Quarter 2010 Results
11. Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Investor-Edge has initiated coverage on ... Medivation Inc. (NASDAQ: MDVN ), Pharmacyclics Inc. ... MKT: SYN), and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). Free ... http://investor-edge.com/register . On Wednesday, October 29, ... the Dow Jones Industrial Average declined 0.18%, to finish ...
(Date:10/30/2014)... SoundConnect , an industry leading ... end users the key to turning this already ... adding voice enablement and hybrid audio conferencing. , ... communication tool that includes presence, instant messaging and ... becomes a comprehensive unified communications solution. Adding the ...
(Date:10/30/2014)... Avure Technologies celebrates a year of success and ... its fleet of high volume High Pressure Processing (HPP) systems. ... return to PackExpo this year, which is where we first ... Jeff Williams, CEO at Avure. “Sales of the new Avure ... meeting the challenges of market demand for higher throughput. We ...
(Date:10/30/2014)... in the development of quantum technologies has been proposed ... published today (28 October) in Nature Communications , ... a new type of flexibly designed microscopic trap for ... and specialised superfast computers, often depend on harnessing the ... these tiny particles are hugely problematic because of the ...
Breaking Biology Technology:Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 2SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 3In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3
... DALLAS, October 14, 2010 ... ... --> ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var r ...
... Inc., a global leader in the research and development of ... its 2010 UCB Crohn,s and Me Scholarship Program ... 31 winners to receive a scholarship worth up to $10,000 ... The scholarship winners include Crohn,s disease patients, ...
... Kenya and Uganda have laid the groundwork for confined ... varieties of maize genetically modified to survive recurrent droughts ... is life, according to a speech given today by ... at the World Food Prize Symposium. Scientists working ...
Cached Biology Technology:The World Market for Diabetes Treatments Now Available at ReportsandReports 2The World Market for Diabetes Treatments Now Available at ReportsandReports 3The World Market for Diabetes Treatments Now Available at ReportsandReports 4The World Market for Diabetes Treatments Now Available at ReportsandReports 5The World Market for Diabetes Treatments Now Available at ReportsandReports 6The World Market for Diabetes Treatments Now Available at ReportsandReports 7The World Market for Diabetes Treatments Now Available at ReportsandReports 8The World Market for Diabetes Treatments Now Available at ReportsandReports 92010 UCB Crohn's and Me Scholarship Winners Announced 22010 UCB Crohn's and Me Scholarship Winners Announced 32010 UCB Crohn's and Me Scholarship Winners Announced 4Scientists prepare for confined field trials of life-saving drought-tolerant transgenic maize 2Scientists prepare for confined field trials of life-saving drought-tolerant transgenic maize 3
(Date:10/29/2014)... China — BGI Tech and Hebei Agricultural University jointly ... genome. Jujube is the most economically important member of ... difficult to sequence due the high level of heterozygosity ... that a genome in the Rhamnaceae (Buckthorn) family has ... Nature Communications . , Jujube is ...
(Date:10/29/2014)... new study on a large cohort of kidney cancer ... of the disease -- and reveals an apparent link ... cancer, particularly in Romania. , The research, by an ... and Genome Quebec Innovation Centre in Montreal, underscores the ... acid. The compound, found in plants of the Aristolochia ...
(Date:10/28/2014)... to expand the Office of Rare Diseases Research ... Sciences (ORDR-NCATS) collaborative Rare Diseases Clinical Research Network ... 22 consortia will work with 98 patient advocacy ... treatments for patients with rare diseases. The collaborations ... 2014 funding from NIH. , Rett syndrome, MECP2 ...
Breaking Biology News(10 mins):BGI Tech and Hebei Agricultural University complete the genome sequencing of the jujube tree 2Study sheds light on genetic architecture of kidney cancer 2Study sheds light on genetic architecture of kidney cancer 3NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 2NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 3
... sapiens migrating out of Africa began encountering Neanderthals, ... of thousands of years before. Despite their differences, ... produced children with genes from both lineages. Today, the ... remain alive in the genomes of humans with European ...
... a single gene in honey bees separates the queens from ... University and Wayne State University unraveled the gene,s inner workings ... Biology Letters . The gene, which is responsible for leg ... of bees, ability to carry pollen. "This gene is ...
... provider of scientific, technical and medical information products ... journal, Pathogenesis . Pathogenesis ... College of Pathologists a professional membership organization committed ... excellence in the practice of Pathology. The College ...
Cached Biology News:When populations collide 2When populations collide 3When populations collide 4Single gene separates queen from workers 2Elsevier announces the launch of open access journal: Pathogenesis 2
ERalpha (Ser 104/106)...
... Phosphatase, Calf Intestinal (CIAP), catalyzes the hydrolysis ... ribo- and deoxyribonucleoside triphosphates. This enzyme is ... linearized cloning vector DNA by removing phosphate ... be used for the dephosphorylation of 5 ...
Mouse CXCR3 Allophycocyanin MAb (Clone 220803)...
Homo sapiens palladin...
Biology Products: